Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regorafenib Also Can Cause Osteonecrosis of the Jaw.
Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F. Antonuzzo L, et al. J Natl Cancer Inst. 2016 Feb 7;108(4):djw002. doi: 10.1093/jnci/djw002. Print 2016 Apr. J Natl Cancer Inst. 2016. PMID: 26857267 No abstract available.
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquenz MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. van de Haar J, et al. Among authors: antonuzzo l. Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2. Nat Med. 2023. PMID: 36864254 Free PMC article. Clinical Trial.
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size.
Sparano C, Rotondi M, Verdiani V, Brunori P, Castiglione F, Bartoli C, Perigli G, Badii B, Vezzosi V, Simontacchi G, Livi L, Antonuzzo L, Maggi M, Petrone L. Sparano C, et al. Among authors: antonuzzo l. J Endocr Soc. 2022 Oct 13;6(12):bvac157. doi: 10.1210/jendso/bvac157. eCollection 2022 Oct 26. J Endocr Soc. 2022. PMID: 36397778 Free PMC article.
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.
Marmorino F, Faggioni L, Rossini D, Gabelloni M, Goddi A, Ferrer L, Conca V, Vargas J, Biagiarelli F, Daniel F, Carullo M, Vetere G, Granetto C, Boccaccio C, Cioni D, Antonuzzo L, Bergamo F, Pietrantonio F, Cremolini C, Neri E. Marmorino F, et al. Among authors: antonuzzo l. Future Oncol. 2023 Jul;19(23):1601-1611. doi: 10.2217/fon-2023-0406. Epub 2023 Aug 14. Future Oncol. 2023. PMID: 37577810
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, Ferrante D, Bower M, Sharkey R, Mirallas O, Plaja A, Cucurull M, Mesia R, Dalla Pria A, Newsom-Davis T, Van Hemelrijck M, Sita-Lumsden A, Apthorp E, Vincenzi B, Di Fazio GR, Tonini G, Pantano F, Bertuzzi A, Rossi S, Brunet J, Lambertini M, Pedrazzoli P, Biello F, D'Avanzo F, Lee AJX, Shawe-Taylor M, Rogers L, Murphy C, Cooper L, Andaleeb R, Khalique S, Bawany S, Ahmed S, Carmona-García MC, Fort-Culillas R, Liñan R, Zoratto F, Rizzo G, Perachino M, Doonga K, Gaidano G, Bruna R, Patriarca A, Martinez-Vila C, Pérez Criado I, Giusti R, Mazzoni F, Antonuzzo L, Santoro A, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Diamantis N, Bertulli R, Fulgenzi CAM, D'Alessio A, Ruiz-Camps I, Saoudi-Gonzalez N, Garcia Illescas D, Medina I, Fox L, Gennari A, Aguilar-Company J, Pinato DJ; OnCovid study group. Cortellini A, et al. Among authors: antonuzzo l. Lancet Oncol. 2023 Apr;24(4):335-346. doi: 10.1016/S1470-2045(23)00056-6. Epub 2023 Mar 7. Lancet Oncol. 2023. PMID: 36898391 Free PMC article.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research; Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R. Di Costanzo F, et al. Among authors: antonuzzo l. J Natl Cancer Inst. 2008 Mar 19;100(6):388-98. doi: 10.1093/jnci/djn054. Epub 2008 Mar 11. J Natl Cancer Inst. 2008. PMID: 18334706 Clinical Trial.
Bevacizumab in non-small cell lung cancer.
Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F. Di Costanzo F, et al. Among authors: antonuzzo l. Drugs. 2008;68(6):737-46. doi: 10.2165/00003495-200868060-00002. Drugs. 2008. PMID: 18416583 Review.
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S. Di Costanzo F, et al. Among authors: antonuzzo l. Clin Drug Investig. 2008;28(10):645-55. doi: 10.2165/00044011-200828100-00005. Clin Drug Investig. 2008. PMID: 18783303
Primary cardiac angiosarcoma: a fatal disease.
Antonuzzo L, Rotella V, Mazzoni F, Doni L, Bianchini D, Garbini F, Maio V, Di Costanzo F. Antonuzzo L, et al. Case Rep Med. 2009;2009:591512. doi: 10.1155/2009/591512. Epub 2009 Aug 20. Case Rep Med. 2009. PMID: 19724650 Free PMC article.
177 results